Population pharmacokinetics of nicotine and its metabolites I. Model development

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 34, Issue 1, 2007, Pages 5-21

  Levi, Micha ^a,b   Dempsey, Delia A ^a,b   Benowitz, Neal L ^a,b   Sheiner, Lewis B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Cotinine; Nicotine; Population pharmacokinetics

Indexed keywords

3' HYDROXYCOTININE; COTININE; CYTOCHROME P450 2A6; DEUTERIUM; NICOTINE;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; FEMALE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; METABOLISM; METABOLITE; NORMAL HUMAN; POPULATION MODEL; PRIORITY JOURNAL; SALIVA ANALYSIS; SALIVA LEVEL; TIME;

ADMINISTRATION, ORAL; ADULT; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; COTININE; DEUTERIUM; FEMALE; HALF-LIFE; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NICOTINE; NICOTINIC AGONISTS; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; SALIVA;

EID: 33846303910     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-006-9027-z     Document Type: Article

References (15)

1. D. Dempsey, P. Tutka, P. Jacob, III, F. Allen, K. Schoedel, R. F. Tyndale and N. L. Benowitz. Nicotine metabolite ratio as an index of CYP2A6 metabolic activity. Clin. Pharmacol. Ther. 76:64-72 (2004).
2. N. L. Benowitz and P. Jacob, III. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin. Pharmacol. Ther. 56:483-493 (1994).
3. N. L. Benowitz, F. Kuyt, P. Jacob, III, R. T. Jones and A. L. Osman. Cotinine disposition and effects. Clin. Pharmacol. Ther. 309:139-142 (1983).
4. J. Hukkanen, P. Jacob, III, and N. L. Benowitz. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57:79-115 (2005).
5. N. L. Benowitz, P. Jacob, III, I. Fong, and S. Gupta. Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine. J. Pharmacol. Exp. Ther. 268:296-303 (1994).
6. N. L. Benowitz and P. Jacob, III. Trans-3′-hydroxycotinine: Disposition kinetics, effects and plasma levels during cigarette smoking. Br. J. Clin. Pharmacol. 51:53-59 (2001).
7. M. Levi, D. Dempsey, N. L. Benowitz, and L. B. Sheiner. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples. II. Model application. J. Pharmacokinet. Pharmacodyn. DOI: 10.1007/s10928-006-9026-0 (2007).
8. M. Curvall, C.-E. Elwin, E. Kazemi-Vala, C. Warholm and C. R. Enzell. The pharmacokinetics of cotinine in plasma and saliva from nonsmoking healthy volunteers. Eur. J. Clin. Pharmacol. 38:281-287 (1990).
9. N. L. Benowitz, P. Jacob, III, C. Denaro, and R. Jenkins. Stable isotope studies of nicotine kinetics and bioavailability. Clin. Pharmacol. Ther. 49:270-277 (1991).
10. S. Zevin, P. Jacob, III, P. Geppetti, and N. L. Benowitz. Clinical pharmacology of oral cotinine. Drug Alcohol Depend. 60:13-18 (2000).
11. 2 in humans. Biol. Mass. Spectrom. 20:247-252 (1991).
12. P. Jacob, III, A. Shulgin, L. Yu, and N. L. Benowitz. Determination of the nicotine metabolite trans-3′-hydroxycotinine in smokers using gas chromatography with nitrogen-selective detection or selected ion monitoring. J. Chromatogr. 583:145-154 (1992).
13. S. L. Beal, and L. B. Sheiner. NONMEM Users Guides. NONMEM Project Group, UCSF, San Francisco, CA, 1992.
14. M. Nakajima, T. Yamamoto, K. Nunoya, T. Yokoi, K. Nagashima, K. Inoue, Y. Funae, N. Shimada, T. Kamataki, and Y. Kuroiwa. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1010-1015 (1996).
15. M. J. Jarvis, M. A. H. Russell, N. L. Benowitz, and C. Feyerabend. Elimination of cotinine from body fluids: Implications for noninvasive measurement of tobacco smoke exposure. Am. J. Public Health 78:696-698 (1988).